NCT05997927

Efficacy and Safety Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 149 (actual)
• Sponsor: Jiangsu vcare pharmaceutical technology co., LTD · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This clinical trial is a multicenter, randomized, double-blind, controlled phase II clinical study.

Conditions

• Moderate to Severe Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	VC005 tablets	VC005 groups repeat administration for 12 weeks
DRUG	VC005 Tablets Placebo	VC005 placebo groups repeat administration for 12 weeks

Timeline

• Start date: 2023-07-20
• Primary completion: 2024-07-09
• Completion: 2024-07-09
• First posted: 2023-08-18
• Last updated: 2024-07-29

Locations

1 site across 1 country: China